DSM-Firmenich, Inscripta forge skin care partnership

DSM-Firmenich and Californian biotech outfit Inscripta have formed a strategic partnership focused on developing what the former claims is a novel and highly sought after well-ageing skin care ingredient.

The partnership will see Inscripta will bring its expertise in microbial strain engineering using its proprietary GenoScaler platform—a next-generation technology which leverages proprietary whole genome engineering to deliver robust industrial scale bio-manufacturing.

“Partnering with DSM-Firmenich allows us to demonstrate the full potential of biotechnology in the beauty industry,” said Sri Kosaraju, President and CEO at Inscripta.

“Our GenoScaler platform, combined with DSM-Firmenich’s vast experience in biotech, presents new opportunities for creating bio-active ingredients that meet the high-performance standards of today’s skin care market, while also addressing the growing demand for sustainability.”

The collaboration between DSM-Firmenich and Inscripta combines scientific innovation and environmental responsibility to drive rapid, cost-effective solutions for customers.

This partnership ensures supply chain security, scalability, consistent quality, and efficient use of natural resources.

“As leaders in biotechnology, at dsm-firmenich we are thrilled to collaborate with Inscripta, a well-respected innovator in biotech strain engineering,” said Parand Salmassinia, President of Beauty & Care at DSM-Firmenich.

“By integrating Inscripta’s scientific knowledge with our biotechnology skincare expertise, we’re set to deliver next-generation well-aging products that offer superior results while contributing to a more sustainable future,” she added.

“Our biotech leadership will ensure that we not only meet consumer expectations but exceed them”.

Latest Issues

NYSCC Suppliers' Day 2025

Javits Center, New York
3rd - 4th June 2025

17th Sun Protection Conference 2025

Royal College of Physicians, London
24 - 25 June 2025